The effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis

Rosenblum, Ira; Flora, L.; Eisenstein, Reuben

doi:10.1016/0021-9150(75)90021-0

Cited by 103 publications

(40 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current evidence suggests that calcium may play a pathogenic role in atherosclerosis (1)(2)(3)(4)(5)(6)(7). In cholesterolfed rabbits, anticalcifying and hypocalcemic agents such as diphosphonates (2)(3)(4)(5), thiophene compounds (6), and EDTA (7) have been demonstrated to exert antiatherogenic effects without reducing the dietinduced hypercholesterolemia.…”

Section: Introductionmentioning

confidence: 99%

Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.

Henry¹,

Bentley²

1981

J. Clin. Invest.

419

View full text Add to dashboard Cite

A B S T R A C T We tested the effects of nifedipine, a calcium antagonist, on atherogenesis in rabbits fed a 2% cholesterol diet. The drug was given orally, 40 mg/dl, and control rabbits received placebo. Nifedipine was well tolerated, and evoked only transient, moderate reductions in arterial pressure. Plasma total cholesterol after 8 wk before killing the rabbits was similar in the placebo and nifedipine-treated groups, averaging 1,903+138 (n = 13) and 1,848+121 mg/dl (n = 13; mean+SE; P > 0.8). In placebo-treated rabbits, aortic lesions stainable with Sudan IV covered 40±5% of the intimal surface, and the cholesterol concentration in aortic tissue was 47±5 mg/g protein.Corresponding values for the aortas from nifedipinetreated rabbits were significantly lower and averaged 17±3% (P < 0.001) and 29±2 mg/g protein (P < 0.001). We conclude that nifedipine suppressed atherogenesis without reducing hypercholesterolemia.

show abstract

Section: Introductionmentioning

confidence: 99%

Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.

Henry¹,

Bentley²

1981

J. Clin. Invest.

419

View full text Add to dashboard Cite

show abstract

“…However, serum Ca and P did not change significantly between SNx and ED-treated groups (data not shown), suggesting that ED does not affect circulating Ca and P levels under the present study conditions. ED has been reported to have anti-atherogenic effects in vivo (27), and ED treatment decreased atherosclerosis in type 2 diabetic patients (28). Inflammatory cells such as macrophages and T lymphocytes play an important role in calcified atherosclerotic lesions.…”

Section: Discussionmentioning

confidence: 99%

Effect of Etidronate on Aortic Calcification and Bone Metabolism in Calcitoriol-Treated Rats With Subtotal Nephrectomy

et al. 2005

View full text Add to dashboard Cite

Abstract. The present study was undertaken to determine the effects of etidronate (ED) on calcitriol-induced aortic calcification and bone metabolism in rats with renal failure. Severe aortic calcification was induced by treatment with calcitriol for 3 weeks in rats in which 5 / 6 of the kidneys were removed (SNx group). Treatment of ED (10 mg / kg) together with calcitriol after subtotal nephrectomy (SNx) significantly inhibited thoracic and abdominal aortic calcification 3 weeks after the operation; however, ED (2 mg / kg) was ineffective. The serum levels of osteocalcin and pyridinoline decreased in ED (10 mg / kg) treated-renal failure rats compared with SNx rats. Total bone mineral density (BMD) in the SNx group was lower than that in the sham group, in which animals were treated with calcitriol after a sham operation. The total BMD value in the ED (10 mg/ kg)-treated group was similar to that in the SNx group, whereas the levels of cancellous BMD were low in the ED (10 mg / kg)-treated rats. Our data show that ED at a dosage that suppresses bone metabolism markedly inhibits vascular calcification in rats with renal failure.

show abstract

“…However, in view of recent ¢ndings suggesting bene¢cial e¡ects of bisphosphonates on cardiovascular risk factors and atherosclerotic disease progression, this equation may need to be changed, 10,30,56 particularly if the bene¢ts of bisphosphonates are of a similar magnitude to those of oestrogen replacement.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular disease and osteoporosis: is there a link between lipids and bone?

Burnett

Vasikaran

2002

Ann Clin Biochem

View full text Add to dashboard Cite

Atherosclerotic heart disease and osteoporosis are both diseases of old age. Evidence is accumulating for a link between vascular and bone disease. Calci cation is a common feature of atherosclerotic plaques, and osteoporosis is associated with both atherosclerosis and vascular calci cation. However, the relationship of vascular calci cation to the pathogenesis of atherosclerosis remains incompletely understood. Hormone replacement therapy has bene cial effects in the prevention of both atherosclerosis and osteoporosis. Bisphosphonates inhibit bone resorption and are used in the treatment of osteoporosis, whereas the statins inhibit cholesterol biosynthesis and are used for the treatment of atherosclerosis. We have reviewed recent advances in the knowledge of the actions of bisphosphonates and statins at the cellular, molecular and end-organ levels in order to examine the relationship between cardiovascular disease and osteoporosis and to explore the link between lipids and bones. These studies suggest that the mechanism of actions of these two classes of drugs at the cellular level may not be mutually exclusive. There are some early clinical data to complement these ndings, suggesting that statins increase bone density and bisphosphonates may have a bene cial effect in vivo on plasma lipid levels and on the atherosclerotic process. Properly designed prospective studies that examine the effect of statins on bone density and fractures, as well as the effects of bisphosphonates on lipid pro les, atherosclerotic progression and cardiovascular morbidity and mortality are needed to de ne clearly the clinical effects and potential new roles for these agents.

show abstract

The effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis

Cited by 103 publications

References 7 publications

Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.

Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.

Effect of Etidronate on Aortic Calcification and Bone Metabolism in Calcitoriol-Treated Rats With Subtotal Nephrectomy

Cardiovascular disease and osteoporosis: is there a link between lipids and bone?

Contact Info

Product

Resources

About